B-Cell Differentiation (CD19)

CD19 is a surface glycoprotein belonging to the immunoglobulin (Ig) superfamily that can act as a central positive response regulator in B cells.1-3 CD19 is expressed during normal B-cell development, and the expression is maintained following malignant transformation of B cells.2-4 The specific expression of CD19 in B-cell lineage lymphomas and leukemias makes CD19 a promising target antigen in B-cell malignancies, like non-Hodgkin lymphomas.2-4

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated


  1. Scheuermann RH and Racila E. Leuk Lymphoma. 1995;18:385-397. PMID: 8528044
  2. Wang K, et al. MAbs. 2012;4:571-577. PMID: 23109152
  3. Naddafi R and Davami F. IJMCM. 2015;4:143-151. PMID: 26629482
  4. Maude SL, et al. Blood. 2015;125:4017-4023. PMID: 25999455